Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

This article was originally published here

With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for each share, 1.00 share of BMS common stock

The post Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply